MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

Rhea-AI Summary

MiNK Therapeutics (NASDAQ: INKT) announced two poster presentations at the Society for Immunotherapy of Cancer's 29th Annual Meeting in Houston, Texas, from November 6-10, 2024. The presentations will showcase new preclinical data from MiNK's iNKT cell programs, agenT-797 and PRAME-TCR.

The first presentation, titled 'AgenT-797 cell therapy can be combined with next-generation immune checkpoint inhibitors (ICI) and / or bi-specific engagers to improve anticancer response,' is scheduled for Friday, November 8th (Abstract Number: 753).

The second presentation, 'PRAME-TCR iNKT cell therapy: Opportunity for best-in-class off-the-shelf solid tumor therapy targeting PRAME,' will take place on Saturday, November 9th (Abstract Number: 374).

MiNK Therapeutics is a clinical-stage biopharmaceutical company focusing on the development of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases.

News Market Reaction

-2.42%

1 alert

-2.42% News Effect

On the day this news was published, INKT declined 2.42%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 29^th Annual Meeting on November 6-10, 2024, in Houston, Texas. The presentations will showcase new preclinical data from MiNK’s iNKT cell programs, agenT-797 and PRAME-TCR.

Presentation Details

Title: AgenT-797 cell therapy can be combined with next-generation immune checkpoint inhibitors (ICI) and / or bi-specific engagers to improve anticancer response

Abstract Number: 753

Date: Friday, November 8^th

Title: PRAME-TCR iNKT cell therapy: Opportunity for best-in-class off-the-shelf solid tumor therapy targeting PRAME

Abstract Number: 374

Session Date: Saturday, November 9^th

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.

Forward Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic and curative potential of agenT-797 and iNKT cells the mechanism of action, potency and safety, interim or top-line data, including statements regarding clinical data of agenT-797, the anticipated benefits of agenT-797 and clinical development plans and timelines. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Investor Contact

917-362-1370

investor@minktherapeutics.com

Media Contact

781-674-4428

communications@minktherapeutics.com

FAQ

When and where will MiNK Therapeutics present its iNKT cell program data?

MiNK Therapeutics will present data from its iNKT cell programs at the Society for Immunotherapy of Cancer's 29th Annual Meeting on November 6-10, 2024, in Houston, Texas.

What are the titles of MiNK Therapeutics' poster presentations at SITC 2024?

The two poster presentations are: 1) 'AgenT-797 cell therapy can be combined with next-generation immune checkpoint inhibitors (ICI) and / or bi-specific engagers to improve anticancer response' and 2) 'PRAME-TCR iNKT cell therapy: Opportunity for best-in-class off-the-shelf solid tumor therapy targeting PRAME'.

What type of data will MiNK Therapeutics (INKT) present at SITC 2024?

MiNK Therapeutics will present new preclinical data from its iNKT cell programs, specifically for agenT-797 and PRAME-TCR therapies.

What is the focus of MiNK Therapeutics' research?

MiNK Therapeutics focuses on the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.